Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TdcP-IPV + hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an investigational vaccine regimen developed by Sanofi Pasteur, consisting of the concurrent administration of a combined tetanus, diphtheria, acellular pertussis, and inactivated poliomyelitis vaccine (Tdap-IPV, specifically TdcP-IPV or Adacel-Polio) and a recombinant hepatitis B vaccine. The regimen is intended for use in adolescents (aged 11-14 years) to provide comprehensive protection against five diseases: tetanus, diphtheria, pertussis, poliomyelitis, and hepatitis B. The Tdap-IPV component contains tetanus and diphtheria toxoids, acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3), and inactivated poliovirus types 1, 2, and 3. The hepatitis B component contains recombinant hepatitis B surface antigen (HBsAg). Clinical trials have demonstrated that concurrent administration of these vaccines is safe and immunogenic, showing no clinically relevant immunologic interactions between the components.
- Brand names
- Adacel-Polio
- Other names
- Tdap-IPV + HepB vaccineTetanus-diphtheria-pertussis-polio and hepatitis B vaccineTdcP-IPV and Hepatitis B vaccine
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)HBsAg (Hepatitis B surface antigen)Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)PRN (Pertactin)TT (Tetanus toxoid)Fimbrial antigen type 3
Beyond the preview
Go deeper on TdcP-IPV + hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TdcP-IPV + hepatitis B vaccine.